Lower Atrial Fibrillation Risk With Sodium-Glucose Cotransporter 2 Inhibitors Than With Dipeptidyl Peptidase-4 Inhibitors in Individuals With Type 2 Diabetes: A Nationwide Cohort Study

Author's summary Limited data are available on whether sodium-glucose cotransporter 2 inhibitors reduce the risk of atrial fibrillation (AF) in individuals with type 2 diabetes. In this study, individuals treated with sodium-glucose cotransporter 2 inhibitors had a lower likelihood of developing AF compared to those treated with dipeptidyl peptidase-4 inhibitors, across various subgroups. These results provide important clues for prevention of this common arrhythmia in individuals with type 2 diabetes.

[1]  E. Braunwald.  Gliflozins in the Management of Cardiovascular Disease. , 2022, The New England journal of medicine.

[2]  Xuehui Liu,et al.  Role of sacubitril-valsartan in the prevention of atrial fibrillation occurrence in patients with heart failure: A systematic review and meta-analysis of randomized controlled trials , 2022, PloS one.

[3]  H. Tse,et al.  Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis , 2021, Cardiovascular Diabetology.

[4]  M. Rutter,et al.  Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes , 2021, Diabetes Care.

[5]  W. Aronow.  Faculty Opinions recommendation of Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial. , 2021, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[6]  Y. Kim,et al.  Atrial fibrillation and kidney function: A bidirectional Mendelian randomization study , 2020, medRxiv.

[7]  Shao‐Wei Chen,et al.  The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors , 2020, Cardiovascular Diabetology.

[8]  Y. Kao Yang,et al.  Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients , 2020, Cardiovascular Diabetology.

[9]  A. Rosengren,et al.  Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: a Swedish cohort study , 2020, Cardiovascular Diabetology.

[10]  Deepak L. Bhatt,et al.  Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial. , 2019, Circulation.

[11]  J. Halperin,et al.  Atrial Fibrillation and Diabetes Mellitus: JACC Review Topic of the Week. , 2019, Journal of the American College of Cardiology.

[12]  L. Fauchier,et al.  C2 HEST Score and Prediction of Incident Atrial Fibrillation in Poststroke Patients: A French Nationwide Study , 2019, Journal of the American Heart Association.

[13]  B. Sinha,et al.  Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. , 2019, Diabetes research and clinical practice.

[14]  A. Gillis,et al.  The Association Between Diabetes Mellitus and Atrial Fibrillation: Clinical and Mechanistic Insights , 2019, Front. Physiol..

[15]  Marc P. Bonaca,et al.  SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials , 2019, The Lancet.

[16]  J. Berger,et al.  The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction: JACC State-of-the-Art Review. , 2018, Journal of the American College of Cardiology.

[17]  D. Bell,et al.  Atrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of anti‐diabetic therapies , 2018, Diabetes, obesity & metabolism.

[18]  G. Lip,et al.  10‐year nationwide trends of the incidence, prevalence, and adverse outcomes of non‐valvular atrial fibrillation nationwide health insurance data covering the entire Korean population , 2018, American heart journal.

[19]  G. Lip,et al.  Increasing trends in hospital care burden of atrial fibrillation in Korea, 2006 through 2015 , 2018, Heart.

[20]  Cheng-Li Lin,et al.  Role of CHA2DS2-VASc score in predicting new-onset atrial fibrillation in patients with type 2 diabetes mellitus with and without hyperosmolar hyperglycaemic state: real-world data from a nationwide cohort , 2018, BMJ Open.

[21]  M. Khan,et al.  Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis , 2018, European journal of preventive cardiology.

[22]  L. See,et al.  Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan , 2017, Cardiovascular Diabetology.

[23]  B. Carstensen,et al.  Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. , 2017, The lancet. Diabetes & endocrinology.

[24]  Hee-Jin Kang,et al.  Data Resource Profile: The National Health Information Database of the National Health Insurance Service in South Korea , 2016, International journal of epidemiology.

[25]  N. Gronich,et al.  Usefulness of CHADS2 and CHA2DS2-VASc Scores in the Prediction of New-Onset Atrial Fibrillation: A Population-Based Study. , 2016, The American journal of medicine.

[26]  Yun Gi Kim,et al.  Dipeptidyl Peptidase-4 Inhibitor Increases Vascular Leakage in Retina through VE-cadherin Phosphorylation , 2016, Scientific Reports.

[27]  G. Lip,et al.  Duration of Diabetes Mellitus and Risk of Thromboembolism and Bleeding in Atrial Fibrillation: Nationwide Cohort Study , 2015, Stroke.

[28]  D. Goff,et al.  Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). , 2014, The American journal of cardiology.

[29]  David D. McManus,et al.  Simple Risk Model Predicts Incidence of Atrial Fibrillation in a Racially and Geographically Diverse Population: the CHARGE‐AF Consortium , 2013, Journal of the American Heart Association.

[30]  J. Pankow,et al.  Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the Atherosclerosis Risk in Communities study , 2011, Heart.

[31]  M. Movahed,et al.  Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. , 2005, International journal of cardiology.

[32]  Deepak L. Bhatt,et al.  Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial. , 2015, Circulation.